ALBANY, New York, March 06, 2017: MarketResearchReports.biz has announced the addition of a new market research report to its report repository. The publication is titled, “EpiCast Report: Hyperparathyroidism - Epidemiology Forecast To 2025.” The study explores the growth trajectory of the market over the last couple of years and the prospects for growth in the coming years. The research publication outlines the factors responsible for the variations in the market and evaluates them meticulously. The effect of certain developments has also been conversed in the research report. It also delivers data on the market shares, marketing strategies, and products of leading companies.
Hyperparathyroidism is a type of disorder that happens in the parathyroid gland and occurs due to the existence of unnecessary growth of the parathyroid hormone in the bloodstream. A significant rise in the parathyroid glands activity owing to inherent abnormal changes leads to variation in the excretion of parathyroid hormone, and is thus known as Primary Hyperparathyroidism or PHPT. Nevertheless, an extrinsic abnormal changes impacting calcium homoeostasis, which triggers the production of PTH and is thus called SHPT. In THPT, a situation of autonomous excretion of PTH generally takes place due to longstanding CKD.
For Sample Copy, click here: http://www.marketresearchreports.biz/sample/sample/928045
In order to project the existing cases of PHPT that have been diagnosed, total current cases of SHPT, and prevalent diagnosed cases of THPT, this epidemiology study was conducted. It was projected in the report that the prevalent diagnosed cases of Primary Hyperparathyroidism will increase to 2,373,547 cases by 2025 from 2,055,167 in 2015 expanding at an Annual Growth Rate of 1.55%. The U.S. is expected to have the leading number of PHPT cases amongst the 7MM over the forecast period. On the other hand, Japan is likely to account for comparatively less number of PHPT cases. The report further predicts that the total number prevalent SHPT cases will rise to 85,592,876 cases by the end of 2025 from 75,326,251 cases in 2015, rising at a 1.36% AGR.
The market for hyperparathyroidism is expected to be driven by the growing prevalence of chronic diseases of the kidney. Moreover, growing number of products in the pipeline is expected to further drive the growth of the market. However, there are certain side effects associated with the treatment of hyperparathyroidism such as decline in serum calcium, muscle spasm, and diarrhea. Low serum calcium level also results in high heart failure risks die degraded myocardial performance and hypotension. These factors are expected to hinder the growth of the market in the coming years.
The report talks about the background of the disease, risk factors associated with it, trends, number of cases prevalent in in HPT, SHPT, and THPT. It further provides epidemiological forecast insight and an analysis of the strengths and limitations.
To order report Call Toll Free: 866-997-4948 or send an email on email@example.com